Etoposide

Etoposide is a chemotherapy drug being studied in several clinical trials for its potential in treating different types of cancer, particularly leukemia and lymphoma. This article explores how etoposide is being used in combination with other drugs or as a standalone treatment to improve outcomes for patients with challenging cancers. We’ll look at its applications in stem cell transplantation and for relapsed or resistant cancers in both children and adults.

Table of Contents

What is Etoposide?

Etoposide is a chemotherapy drug used to treat various types of cancer. It’s also known by other names such as VP-16 or VP-16,213[1]. Etoposide belongs to a class of drugs called topoisomerase inhibitors, which work by interfering with the cancer cells’ ability to divide and grow[2].

How Etoposide Works

Etoposide targets a specific protein in cancer cells called topoisomerase II. This protein is essential for cancer cells to divide and multiply. By inhibiting topoisomerase II, etoposide prevents cancer cells from growing and spreading, ultimately leading to their death[2]. Understanding how etoposide affects cancer cells helps researchers develop more effective treatment strategies and combinations with other drugs.

Conditions Treated with Etoposide

Etoposide is used to treat various types of cancer, including:

  • Small Cell Lung Cancer (SCLC): This is an aggressive form of lung cancer for which etoposide is commonly used in combination with other drugs[2][3].
  • Non-Hodgkin’s Lymphoma: A type of blood cancer affecting the lymphatic system[4].
  • Brain and Central Nervous System Tumors: Including ependymomas, which are tumors that form in the brain or spinal cord[1].
  • Acute Leukemias: Cancers of the blood and bone marrow[5].
  • Testicular Cancer: Particularly in cases of seminoma, a type of testicular cancer[6].

How Etoposide is Administered

Etoposide can be given in different ways, depending on the specific treatment plan and type of cancer:

  • Intravenous (IV) Injection: Etoposide is often given through a vein over a period of time. For example, it may be administered daily for 3-5 days as part of a treatment cycle[1][3].
  • Oral Capsules: In some cases, etoposide can be taken by mouth in capsule form. This allows for more convenient at-home treatment in certain situations[2][4].

The dosage and schedule of etoposide administration can vary based on factors such as the type of cancer, the patient’s overall health, and whether it’s being used alone or in combination with other treatments.

Etoposide in Combination Therapies

Etoposide is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combinations include:

  • Etoposide + Cisplatin: This combination is frequently used in treating small cell lung cancer and other solid tumors[1][7].
  • Etoposide + Carboplatin: Another combination used in lung cancer treatment[6].
  • Etoposide + Mitoxantrone: Used in treating certain types of leukemia[8].
  • Etoposide + Cyclophosphamide + Cisplatin: A combination used in treating lymphomas and other cancers[9].

These combinations are designed to target cancer cells in multiple ways, potentially increasing the effectiveness of treatment while managing side effects.

Potential Side Effects

Like all chemotherapy drugs, etoposide can cause side effects. It’s important to discuss these with your healthcare provider. Common side effects may include:

  • Lowered blood counts (white blood cells, red blood cells, and platelets), which can increase the risk of infection, anemia, and bleeding
  • Nausea and vomiting
  • Hair loss
  • Fatigue
  • Loss of appetite
  • Mouth sores

Your healthcare team will monitor you closely for these and other potential side effects and may adjust your treatment plan as needed[7].

Ongoing Research and Clinical Trials

Researchers continue to study etoposide to improve its effectiveness and explore new applications. Some areas of ongoing research include:

  • Combination with newer drugs: Studies are looking at combining etoposide with newer targeted therapies or immunotherapies to enhance treatment outcomes[7].
  • Personalized medicine approaches: Research is exploring how genetic factors might influence a patient’s response to etoposide, potentially leading to more tailored treatment plans[2].
  • New formulations: Scientists are investigating different ways of delivering etoposide to improve its effectiveness or reduce side effects.
  • Expanded use in other cancer types: Clinical trials are exploring the use of etoposide in treating additional types of cancer or at different stages of disease[10].

These ongoing studies aim to improve treatment outcomes and quality of life for patients receiving etoposide-based therapies.

Aspect Details
Cancer Types Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin’s Lymphoma, Metastatic Breast Cancer
Patient Groups Children, Adolescents, Adults with relapsed or resistant cancers
Administration Methods Intravenous infusion, Oral capsules
Common Combinations Clofarabine, Cyclophosphamide, Fludarabine, ATG, Treosulfan, Thiotepa
Treatment Goals Improve survival rates, Increase remission rates, Prepare for stem cell transplantation
Key Outcomes Measured Event-free survival, Overall survival, Response rates, Toxicity levels
Special Applications Conditioning regimens for stem cell transplantation, Treatment for high-risk or relapsed cancers

Ongoing Clinical Trials on Etoposide

  • Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on Glofitamab and Drug Combination for Children and Young Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Czechia Denmark France Germany Hungary Italy +2
  • Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    1 1 1
    Austria Denmark Finland France Germany Ireland +5
  • Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium Czechia Denmark France Germany +4
  • Study on Metronomic Chemotherapy for Children and Teenagers with Relapsed or Refractory Wilms Tumor Using Vincristine, Irinotecan, Etoposide, Temozolomide, and Isotretinoin

    Recruiting

    1 1 1
    France
  • Study on Retinoblastoma Treatment: Evaluating the Effectiveness of Topotecan, Vincristine Sulfate, and Etoposide in Patients Eligible for Conservative Therapy

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on Dinutuximab Beta with Chemotherapy for Children and Teens with Newly Diagnosed High-Risk Neuroblastoma

    Recruiting

    1 1 1
    Austria France Germany Italy The Netherlands Poland +1
  • Study on Mifamurtide with Chemotherapy for Patients with High-Risk Osteosarcoma

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on Pembrolizumab and Olaparib for Patients with Extensive-Stage Small-Cell Lung Cancer

    Recruiting

    1 1 1
    Italy
  • Study on Ruxolitinib and Drug Combination for Critically Ill Adults with Acquired Hemophagocytic Syndrome

    Recruiting

    1 1 1
    France

Glossary

  • Acute Lymphoblastic Leukemia (ALL): A type of cancer that affects the blood and bone marrow, causing the body to produce too many immature white blood cells called lymphoblasts.
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow that leads to the rapid growth of abnormal white blood cells that interfere with normal blood cell production.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy stem cells, which can develop into new, healthy blood cells.
  • Graft-versus-Host Disease (GvHD): A potential complication of stem cell transplantation where the donor's immune cells attack the recipient's tissues.
  • Remission: A period during which cancer symptoms lessen or disappear, though the cancer may still be present in the body.
  • Relapsed Cancer: Cancer that returns after a period of improvement or remission.
  • Refractory Cancer: Cancer that does not respond to treatment or stops responding after initial improvement.
  • Total Body Irradiation (TBI): A form of radiotherapy used to prepare the body for stem cell transplantation by suppressing the immune system and killing cancer cells.
  • Antithymocyte Globulin (ATG): An antibody used to suppress the immune system, often used in stem cell transplantation to prevent rejection.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.

References

  1. https://clinicaltrials.gov/study/NCT00002876
  2. https://clinicaltrials.gov/study/NCT01064466
  3. https://clinicaltrials.gov/study/NCT06049966
  4. https://clinicaltrials.gov/study/NCT00002880
  5. https://clinicaltrials.gov/study/NCT00002912
  6. https://clinicaltrials.gov/study/NCT01887340
  7. https://clinicaltrials.gov/study/NCT01579929
  8. https://clinicaltrials.gov/study/NCT00002688
  9. https://clinicaltrials.gov/study/NCT00002488
  10. https://clinicaltrials.gov/study/NCT01294670